How can discoveries from the other areas be harnessed for innovative microbiome-based diagnostic, preventive, and therapeutic strategies?
Scientists in Research Area D will translate knowledge acquired in sections A, B and C into innovative, microbiome-centered, and personalized strategies of risk stratification, diagnosis, prevention and therapy against antibiotic-resistant bacterial pathogens (ARBPs). Notably, the resistomes of risk patients will be analyzed by metagenome sequencing of fecal samples and used to implement patient-specific therapies.
Moreover, combined resistome data will be used to adjust general antibiotic stewardship guidelines at the University Hospital Tübingen. In parallel, the commensals, the phages and the host-derived antimicrobial molecules with the capacity to selectively eliminate facultative pathogens from human microbiomes such as those identified in Research Area A, B, and C will be tested as promising agents to prevent infections by ARBPs.
University Hospital Tübingen
Immunology and Oncology